Dr Doug Wilson to step down from AFT Board

22 July 2022
Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces that Dr Doug Wilson will step down from its Board of Directors at the conclusion of the company’s Annual Meeting of Shareholders on 5 August 2022.
Dr Wilson joined the AFT Board in 2012 following a distinguished and diverse career in academia and business and with deep experience spanning pharmaceutical research, development and commercialisation.
AFT Pharmaceuticals Chair David Flacks said: “Doug’s experience and expertise have brought significant value to the Board and the AFT business. The combination of his healthcare and commercial experience has been present during a number of significant milestones including our NZX and ASX listings, product negotiations and meetings with regulators around the globe. He has also brought to the board table a world view and a genuine and abiding care for people.”
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “Doug has advised AFT since 2008 and with his huge experience in drug development and regulatory issues on a global level, his contribution has been invaluable. Doug is a great teacher - we have soaked up his wisdom and are in a good place to continue our existing and new R&D programmes. We certainly are grateful for all of Doug’s help and thank him sincerely.”
Dr Doug Wilson – Career overview
Dr Doug Wilson joined the AFT Board in 2012 after a diverse and distinguished career.
His first job in medicine was as a nurse at Auckland Hospital during a student vacation. Upon graduating from Otago University medical school, he undertook postgraduate training in medicine, blood and kidney diseases and research. After moving to the UK he gained a PhD training in haematology and immunology.
He returned to New Zealand and was appointed an associate professor at Auckland Medical School, and this was followed by other academic roles including visiting professor at the King Saud University in Riyadh, Saudi Arabia.
At the age of 50 he opted for a new career in business, joining the German pharmaceutical company Boehringer Ingelheim, first as its New Zealand Medical Director and ending his tenure as the company’s worldwide head of Medical Research and Regulatory Affairs.
During this time, he led teams that developed and commercialised new drugs for hypertension, HIV, chronic lung diseases, strokes, heart attacks, prostatic disease among many others.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:
Investors Media
Dr Hartley Atkinson Coran Lill
Managing Director The Project
AFT Pharmaceuticals Tel: +64 27 342 3836
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and to out-license / distribute our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website: www.aftpharm.com.

---

Announcement PDF